For patients managing a chronic condition, the most consistent point of contact is often not a doctor's office, but the local pharmacy. Scriptify, a Boston-based venture, is betting that a telemedicine layer can turn that foundation into a formal network, connecting community pharmacists directly with patients and prescribers to streamline management for conditions like diabetes or hypertension [Harvard Innovation Labs, 2024]. The company's vision, incubated at Harvard and MIT, positions the neighborhood pharmacy not just as a dispensary, but as the hub of a distributed chronic care model.
A pharmacy-first approach to chronic disease
Scriptify's product claims center on enabling retail pharmacies to identify and monitor patients with chronic diseases within their communities [MIT Solve, 2024]. The proposed platform would provide the digital infrastructure for pharmacists to expand services and help prevent medication complications [Scriptifyrx.com, 2024; Harvard Innovation Labs, 2024]. While the company mentions using AI to assist, it emphasizes that real clinicians guide every step [Harvard Innovation Labs, 2024]. This framing suggests a tool designed to augment, not replace, clinical judgment, a sensible approach for a sector tightly regulated by state boards of pharmacy and the FDA.
The academic accelerator path
Without disclosed venture funding, Scriptify's trajectory has been shaped by its affiliations with prestigious academic programs. The company was founded in 2020 and has participated in the Harvard Innovation Labs Student i-lab, was selected as a Solver by MIT Solve, and joined the TNT pre-seed AI accelerator [hsph.harvard.edu, retrieved 2026; MIT Solve, 2024; TNT].
| Team Member | Role | Background |
|---|---|---|
| Nomase Iyamu | CEO & Founder | Ex-pharmaceutical researcher, financial founder |
| Dr. Jana Attia | Pharmacy Officer | Clinical pharmacy, precision medicine |
| Dominic Co | Innovation & Design Engineer | Engineering and design |
Navigating a cluttered brand landscape
The company's most immediate challenge is one of clarity. The public footprint is light, with its primary domain not resolving to a live site [Perplexity Sonar Pro Brief, retrieved 2024]. More significantly, the name "Scriptify" is used by multiple other companies in different industries, from AI productivity tools to content creation platforms [LinkedIn; GitHub; Tracxn]. This creates a significant headwind for searchability and market recognition. Furthermore, the competitive set includes established players like TelePharm and HubRx. Scriptify's differentiation must be sharply defined; its academic origins and focus on chronic care management could provide a wedge, but that thesis remains unproven without public customer deployments.
The next twelve months
For Scriptify, the coming year is about moving from academic prototype to commercial pilot. The signals to watch are concrete:
- First pharmacy partner. A named, live deployment with a community pharmacy or small chain would validate the core integration.
- Regulatory clarity. How the platform navigates state-by-state telepharmacy laws and integrates with existing pharmacy management systems will be a major hurdle.
- Seed funding. Transitioning from accelerator support to a priced seed round would provide the capital needed for commercial hiring.
The ambition sits at a critical junction in community healthcare. If Scriptify can cut through the noise of its own name and translate its academic pedigree into a simple, compliant tool, it might just give the corner pharmacy a new script to follow.